<DOC>
	<DOCNO>NCT01834404</DOCNO>
	<brief_summary>Our overall goal determine effect Phentermine Topiramate ER gastric emptying , gastric accommodation , satiety , satiation obese participant .</brief_summary>
	<brief_title>Peripheral Pharmacodynamics Phentermine-Topiramate Obese Patients</brief_title>
	<detailed_description>Investigators propose randomize controlled trial combination phentermine topiramate ER versus placebo give orally 10-15 day . At visit 1 subject brief interview , body measurement , complete 4 questionnaire rule gastrointestinal significant psychological distress . At visit 2 subject satiation/nutrient drink test . They drink nutrient drink reach maximum volume could tolerate , symptom record blood sample take 4 time . They randomize one arm , receive 5 day supply study medication placebo . The dose study drug phentermine 3.75 mg / topiramate 23 mg day 1-5 . At visit 3 subject return pick nine day supply study medication placebo . The dose study drug increase phentermine 7.5 mg / topiramate 46 mg day 6-14 . At visit 4 subject underwent imaging measure volume stomach external camera revolve around abdomen lie table . Stomach volume check fasting , start 10 min intravenous injection radioactive material . The subject ingest liquid nutrient drink 2 image obtain 30 minute . On day , subject participate eat meal , start 4 hour ingestion liquid nutrient drink . At visit 5 subject repeat satiation/nutrient drink test . They drink nutrient drink reach maximum volume could tolerate , symptom record blood sample take 4 time . At visit 6 subject take part gastric empty scintigraphy test . Subjects give scramble egg breakfast toast glass milk . The eggs milk contain small amount radioactive substance . At completion meal , subject stood front special camera picture take specific interval .</detailed_description>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Phentermine</mesh_term>
	<criteria>INCLUSION CRITERIA : Obese subject BMI &gt; 30 Kg/m^2 . Otherwise healthy individual currently treatment cardiac , pulmonary , gastrointestinal , hepatic , renal , hematological , neurological , endocrine ( hyperglycemia require medical therapy ) unstable psychiatric disease . Women childbearing potential negative pregnancy test initiation medication . EXCLUSION CRITERIA : Weight &gt; 300 lb , limit safety SPECT scanner Concomitant use appetite suppressant ( i.e. , caffeine base diethylpropion ) orlistat ( Xenical® ) Uncontrolled hypertension ( Blood pressure great 160/90 mmHg ) Concentration fast glucose great 240 mg/dl Concentration triglyceride great 400 mg/dl Type 1 Diabetes Use antidiabetic drug metformin , History nephrolithiasis , Recurrent major depression , presence history suicidal behavior ideation intent act , current substantial depressive symptom ( Patient Health Questionnaire9 , 21 total score ≥10 ) . Concomitant use Monoamine Oxidase Inhibitors ( MAOI ) ( i.e. , phenelzine , selegiline ) , serotonergic agent , centrally act appetite suppressant Significant psychiatric dysfunction base upon screen Hospital Anxiety Depression Scale [ HADS ] selfadministered alcoholism screen test ( SAAST , substance abuse ) questionnaire eat weight pattern ( binge eat disorder bulimia ) . If dysfunction identify Hospital Anxiety Depression Scale ( HADS ) score ≥11 subscales difficulty substance eat disorder , participant exclude give referral letter his/her primary care doctor appraisal followup . End stage renal disease liver cirrhosis Intake medication could interfere interpretation study cause drug interaction ( i.e. , ketoconazole , erythromycin ) . Specifically , birth control pill , estrogen replacement therapy , thyroxine replacement permissible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Obesity</keyword>
	<keyword>BMI</keyword>
	<keyword>Incretin</keyword>
	<keyword>Satiety</keyword>
	<keyword>Phentermine</keyword>
	<keyword>Topiramate</keyword>
</DOC>